Paper36642016
Soluble CD25 imposes a low-zone IL-2 signaling environment that favors competitive outgrowth of antigen-experienced CD25high regulatory and memory T cells.
Nickle RA and 3 others. Cell Immunol, 2023. Cited by 17 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Soluble CD25 imposes a low-zone IL-2 signaling environment that favors competitive outgrowth of antigen-experienced CD25high regulatory and memory T cells. Papers, record 36642016. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36642016
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| T-Lymphocytes, Regulatory | Major topic |
| Interleukin-2 | Major topic |
| Humans | |
| Mice | |
| Animals | |
| Memory T Cells | |
| Interleukin-2 Receptor alpha Subunit | |
| Forkhead Transcription Factors |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 AI126398 | NIAID NIH HHS | United States | R01AI126398 | PubMed and NIH | NIH RePORTER |
| R01 NS072150 | NINDS NIH HHS | United States | R01NS072150 | PubMed and NIH | NIH RePORTER |
| S10 OD021615 | NIH HHS | United States | S10OD021615 | PubMed and NIH | NIH RePORTER |
References110
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32919253 | Interleukin-15 in autoimmunity. | Cytokine | 2020 | https://conductscience.org/library/papers/32919253 | PubMed |
| 2 | 30742970 | CD25 deficiency: A new conformational mutation prevents the receptor expression on cell surface. | Clin Immunol | 2019 | https://conductscience.org/library/papers/30742970 | PubMed |
| 3 | 17475784 | TGF-beta1 modulates Foxp3 expression and regulatory activity in distinct CD4+ T cell subsets. | J Leukoc Biol | 2007 | https://conductscience.org/library/papers/17475784 | PubMed |
| 4 | 28497365 | Clinical utility of soluble interleukin-2 receptor in hemophagocytic syndromes: a systematic scoping review. | Ann Hematol | 2017 | https://conductscience.org/library/papers/28497365 | PubMed |
| 5 | 10358772 | The IL-4 receptor: signaling mechanisms and biologic functions. | Annu Rev Immunol | 1999 | https://conductscience.org/library/papers/10358772 | PubMed |
| 6 | 33633742 | Treg Therapies Revisited: Tolerance Beyond Deletion. | Front Immunol | 2020 | https://conductscience.org/library/papers/33633742 | PubMed |
| 7 | 16757567 | Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. | Proc Natl Acad Sci U S A | 2006 | https://conductscience.org/library/papers/16757567 | PubMed |
| 8 | 32619646 | The IL-2 - IL-2 receptor pathway in health and disease: The role of the soluble IL-2 receptor. | Clin Immunol | 2020 | https://conductscience.org/library/papers/32619646 | PubMed |
| 9 | 23077668 | Soluble IL-2Rα (sCD25) exacerbates autoimmunity and enhances the development of Th17 responses in mice. | PLoS One | 2012 | https://conductscience.org/library/papers/23077668 | PubMed |
| 10 | 18395861 | Human regulatory T cells and autoimmunity. | Eur J Immunol | 2008 | https://conductscience.org/library/papers/18395861 | PubMed |
| 11 | 32386776 | Biological functions and therapeutic opportunities of soluble cytokine receptors. | Cytokine Growth Factor Rev | 2020 | https://conductscience.org/library/papers/32386776 | PubMed |
| 12 | 33303781 | Cathepsin S provokes interleukin-6 (IL-6) trans-signaling through cleavage of the IL-6 receptor in vitro. | Sci Rep | 2020 | https://conductscience.org/library/papers/33303781 | PubMed |
| 13 | 3086363 | An analysis of the cellular requirements for the production of soluble interleukin-2 receptors in vitro. | J Clin Immunol | 1986 | https://conductscience.org/library/papers/3086363 | PubMed |
| 14 | 21037099 | Cutting edge: mechanisms of IL-2-dependent maintenance of functional regulatory T cells. | J Immunol | 2010 | https://conductscience.org/library/papers/21037099 | PubMed |
| 15 | 33868284 | Low-Dose IL-2 Therapy in Autoimmune and Rheumatic Diseases. | Front Immunol | 2021 | https://conductscience.org/library/papers/33868284 | PubMed |
| 16 | 24517429 | Signals and pathways controlling regulatory T cells. | Immunol Rev | 2014 | https://conductscience.org/library/papers/24517429 | PubMed |
| 17 | 18062768 | The biology of interleukin-2. | Annu Rev Immunol | 2008 | https://conductscience.org/library/papers/18062768 | PubMed |
| 18 | 11585388 | Interleukin-2 promotes antigenic reactivity of rested T cells but prolongs the postactivational refractory phase of activated T cells. | Cell Immunol | 2001 | https://conductscience.org/library/papers/11585388 | PubMed |
| 19 | 22721971 | Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. | Diabetes | 2012 | https://conductscience.org/library/papers/22721971 | PubMed |
| 20 | 25634360 | Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. | J Autoimmun | 2015 | https://conductscience.org/library/papers/25634360 | PubMed |
Cited by12
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 17 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42906129 | A human self-stimulatory CD4+ T cell antigen-presenting cell subset presents and recognizes agonistic self-antigens to sustain exponential autologous clonal expansion. | J Immunol | 2026 | https://conductscience.org/library/papers/42906129 | PubMed |
| 42258128 | Peripheral blood IFN-γ-producing T-cell subsets and soluble IL-2 receptor as independent prognostic biomarkers in NSCLC treated with immune checkpoint inhibitor-based therapy. | Discov Oncol | 2026 | https://conductscience.org/library/papers/42258128 | PubMed |
| 42232508 | Type 1-polarized DC immunotherapeutic contains heterogeneous populations with IL-12p70 production restricted to a rare subset. | bioRxiv | 2026 | https://conductscience.org/library/papers/42232508 | PubMed |
| 41477466 | Biomarkers Detecting the Activity of ANCA-Associated Vasculitis: A Systematic Literature Review. | Int J Nephrol | 2025 | https://conductscience.org/library/papers/41477466 | PubMed |
| 41463121 | Proteomics Reveals Differential Diagnosis Biomarkers Between Sepsis and Hemophagocytic Syndrome. | Biomedicines | 2025 | https://conductscience.org/library/papers/41463121 | PubMed |
| 41459501 | IL-33 and IL-3 synergistically induce CD25 expression on human basophils without functional IL-2 signaling: a potential marker of severe COVID-19. | Front Immunol | 2025 | https://conductscience.org/library/papers/41459501 | PubMed |
| 40963621 | Hypoxia and activation of hypoxia inducible factor alpha as influencers of inflammatory helper T cells in autoimmune disease - a link between cancer and autoimmunity. | Front Immunol | 2025 | https://conductscience.org/library/papers/40963621 | PubMed |
| 40431708 | A Novel Antiviral Therapeutic Platform: Anchoring IFN-β to the Surface of Infectious Virions Equips Interferon-Evasive Virions with Potent Antiviral Activity. | Viruses | 2025 | https://conductscience.org/library/papers/40431708 | PubMed |
| 40148963 | Breast cancer scoring based on a multiplexed profiling of soluble and cell-associated (immune) markers facilitates the prediction of pembrolizumab therapy. | Cancer Cell Int | 2025 | https://conductscience.org/library/papers/40148963 | PubMed |
| 40139976 | Safety, pharmacokinetics, and pharmacodynamics of MK-6194, an IL-2 mutein designed to selectively activate regulatory T cells: single ascending dose and multiple ascending dose trial data. | Immunohorizons | 2025 | https://conductscience.org/library/papers/40139976 | PubMed |
| 40038821 | A blood-based liquid biopsy analyzing soluble immune checkpoints and cytokines identifies distinct neuroendocrine tumors. | J Exp Clin Cancer Res | 2025 | https://conductscience.org/library/papers/40038821 | PubMed |
| 39403561 | Three doses of Sars-CoV-2 mRNA vaccine in older adults result in similar antibody responses but reduced cellular cytokine responses relative to younger adults. | Vaccine X | 2024 | https://conductscience.org/library/papers/39403561 | PubMed |
Genes22
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36642016
GET https://conductscience.org/api/papers/v1/36642016/references?page=2